Tuberculosis is both curable and preventable, yet each year, it still kills more people than any other infectious disease. One reason is that current treatments hinge on rifampicin, an antibiotic that ...

African scientists have developed a nanoscale drug delivery system to treat pericarditis, a drug-resistant and lethal tuberculosis (TB). The scientists' system can breach the heart's protective ...

For 2007, the WHO estimated 511,000 cases of multidrug-resistant (MDR)-TB, representing approximately 5% of all TB cases worldwide. Extensively drug-resistant (XDR-TB) strains have been detected in at ...

New drugs for hard-to-treat tuberculosis strains may be fast rendered ineffective themselves if incorrectly used, a report warned Thursday, on the eve of World TB Day. Antibiotics such as bedaquiline, ...

Across Europe, tuberculosis (TB) is once again raising alarm, particularly the extensively drug-resistant form (XDR-TB), which is proving as deadly as before antibiotics were discovered. A large ...

Tuberculosis (TB) is the world's biggest infectious disease killer with multidrug-resistant TB (MDR-TB) posing a particular threat to global health. A study shows that resistance to the new MDR-TB ...

An investigational three-drug regimen that could cut tuberculosis (TB) treatment from six months to four is now in a phase 3 clinical trial, arriving as the World Health Organization (WHO) reports an ...

Researchers found that pairing the antibiotic rifampicin with a second compound turned multidrug resistance into a weakness—providing proof of concept for using basic science to design life-saving ...

A new systematic review of fifteen studies finds that only 74.2 percent of drug-resistant tuberculosis patients in Cameroon ...

Tuberculosis (TB) remains a global health challenge, affecting millions each year. In 2023, an estimated 10.8 million people contracted TB, with 1.25 million deaths, according to the World Health ...

Please provide your email address to receive an email when new articles are posted on . Three all-oral 9-month treatments for drug-resistant tuberculosis were found to be noninferior to standard ...

Sydney researchers have found that Levofloxacin substantially reduces risk of drug-resistant tuberculosis. This discovery offers new hope against a disease that infects more than 400,000 people ...